FDA Finalizes 3 Biosimilars Guidances
The U.S. Food and Drug Administration on Tuesday finalized a trio of guidances explaining its standards for approval of biosimilars, making noteworthy revisions to a number of policies floated more than...To view the full article, register now.
Already a subscriber? Click here to view full article